Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Arcturus Therapeutics's ARCT-810?
ARCT-810 is a gene therapy commercialized by Arcturus Therapeutics, with a leading Phase II program in Ornithine-Transcarbamylase Deficiency. According to...
Data Insights
ARCT-810 by Arcturus Therapeutics for Ornithine-Transcarbamylase Deficiency: Likelihood of Approval
ARCT-810 is under clinical development by Arcturus Therapeutics and currently in Phase II for Ornithine-Transcarbamylase Deficiency. According to GlobalData, Phase...